T4 Phage and Its Head Surface Proteins Do Not Stimulate Inflammatory Mediator Production

Abstract

Viruses are potent activators of the signal pathways leading to increased cytokine or ROS production. The effects exerted on the immune system are usually mediated by viral proteins. Complementary to the progress in phage therapy practice, advancement of knowledge about the influence of bacteriophages on mammalian immunity is necessary. Particularly, the potential ability of phage proteins to act like other viral stimulators of the immune system may have strong practical implications for the safety and efficacy of bacteriophage therapy. Here we present studies on the effect of T4 phage and its head proteins on production of inflammatory mediators and inflammation-related factors: IL-1α, IL-1β, IL-2, IL-6, IL-10, IL-12 p40/p70, IFN-γ, TNF-α, MCP-1, MIG, RANTES, GCSF, GM-CSF and reactive oxygen species (ROS). Plasma cytokine profiles in an in vivo mouse model and in human blood cells treated with gp23*, gp24*, Hoc and Soc were evaluated by cytokine antibody arrays. Cytokine production and expression of CD40, CD80, CD86 and MHC class II molecules were also investigated in mouse bone marrow-derived dendritic cells treated with whole T4 phage particle or the same capsid proteins. The influence of T4 and gp23*, gp24*, Hoc and Soc on reactive oxygen species generation was examined in blood cells using luminol-dependent chemiluminescence assay. In all performed assays, the T4 bacteriophage and its capsid proteins gp23*, gp24*, Hoc and Soc did not affect production of inflammatory-related cytokines or ROS. These observations are of importance for any medical or veterinary application of bacteriophages.

The impact of orally administered phages on host immune response and surrounding microbial communities

“…Taken together, these data indicate that phage treatment did not elicit an appreciable acute immune response. Similar results were reported by Miernikiewicz et al 18 Our study also investigated the impact of phage treatment on pig gut microbiome. In general, the gut microbiome of pigs in our study, regardless of treatments, resembled the typical swine microbiome shown previously.…”

Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages*

“…Second, contrary to viruses used in viral gene therapy, bacteriophages are unable to penetrate eukaryotic cells. Third, from an immunological point of view, bacteriophages do not elicit a significant acute inflammatory response in mammals as shown by several studies on both purified structural proteins and entire virions (17,54). In our work, we observed a non-significant increase in BAL fluid total proteins in bacteriophage-treated mice compared to control mice 6 hours post-infection (208 and 140 µg/mL, respectively).…”

Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections – anin vivostudies overview

“…Miernikiewicz et al () examined the impact of purified bacteriophage T4 and the highly purified surface proteins of its head (i.e. gp23 and gp24) on the profiles of inflammatory mediators and other inflammation‐related factors (i.e.…”